By Drug Target Review2025-12-08T09:00:32
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-01-26T13:22:42
Sponsored by bit.bio
2023-03-03T14:06:14
Sponsored by Bio-Techne
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2023-04-04T15:03:09
Sponsored by Agilent
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
Site powered by Webvision Cloud